On May 4, 2016, the U.S. Court of Appeals for the Third Circuit announced its decision in Eisai, Inc. v. Sanofi Aventis U.S., LLC,  rejecting antitrust claims predicated on a supplier’s market-share discount program and other promotional tactics. While the court’s decision adds some definition to an amorphous standard that has long plagued companies with strong U.S. market positions, bundling and other aggressive price-based behavior by such firms unfortunately remains an issue that poses uncertainty and antitrust risk. Nevertheless, the Eisai decision reinforces several key tenets of U.S. monopolization law, including that lack of coercion of customers is key to avoiding antitrust liability and that the result of bundling must be to injure competition and not just one or more
The US Court of Appeals for the Third Circuit rejects antitrust claims predicated on a supplier’s market-share discount program and other promotional tactics (Eisai / Sanofi)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.